Legal Advantage Investments Inc. Invests $1.24 Million in GRAIL, Inc. $GRAL

Legal Advantage Investments Inc. purchased a new position in shares of GRAIL, Inc. (NASDAQ:GRAL) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 21,000 shares of the company’s stock, valued at approximately $1,242,000. Legal Advantage Investments Inc. owned about 0.06% of GRAIL at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Teacher Retirement System of Texas grew its holdings in shares of GRAIL by 5.5% during the second quarter. Teacher Retirement System of Texas now owns 8,538 shares of the company’s stock worth $439,000 after purchasing an additional 447 shares during the last quarter. Parallel Advisors LLC lifted its position in GRAIL by 24.1% during the 2nd quarter. Parallel Advisors LLC now owns 2,313 shares of the company’s stock worth $119,000 after buying an additional 449 shares in the last quarter. Crown Wealth Group LLC lifted its position in GRAIL by 5.9% during the 2nd quarter. Crown Wealth Group LLC now owns 8,986 shares of the company’s stock worth $462,000 after buying an additional 500 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in GRAIL by 28.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock worth $76,000 after acquiring an additional 623 shares during the last quarter. Finally, HighTower Advisors LLC increased its position in GRAIL by 5.7% in the 1st quarter. HighTower Advisors LLC now owns 11,591 shares of the company’s stock valued at $296,000 after acquiring an additional 627 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Morgan Stanley upped their target price on shares of GRAIL from $85.00 to $110.00 and gave the stock an “equal weight” rating in a research report on Monday, December 1st. Canaccord Genuity Group upped their price objective on GRAIL from $85.00 to $105.00 and gave the stock a “buy” rating in a report on Monday, November 17th. Guggenheim upgraded GRAIL from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a research report on Wednesday, November 12th. UBS Group set a $75.00 target price on GRAIL in a research note on Friday, October 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, GRAIL presently has a consensus rating of “Hold” and a consensus target price of $97.50.

Insider Activity

In other GRAIL news, President Joshua J. Ofman sold 81,385 shares of the firm’s stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $62.50, for a total transaction of $5,086,562.50. Following the transaction, the president owned 396,797 shares in the company, valued at approximately $24,799,812.50. This trade represents a 17.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert P. Ragusa sold 7,239 shares of the business’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $68.88, for a total value of $498,622.32. Following the transaction, the chief executive officer owned 727,388 shares of the company’s stock, valued at $50,102,485.44. The trade was a 0.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 113,295 shares of company stock worth $7,380,888 in the last three months.

GRAIL Stock Performance

GRAL opened at $87.88 on Tuesday. The company has a fifty day moving average price of $91.22 and a two-hundred day moving average price of $60.81. The firm has a market capitalization of $3.43 billion, a PE ratio of -7.56 and a beta of 4.22. GRAIL, Inc. has a 52 week low of $16.56 and a 52 week high of $115.76.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($2.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.40) by $0.94. GRAIL had a negative return on equity of 15.69% and a negative net margin of 286.43%.The company had revenue of $36.19 million for the quarter, compared to the consensus estimate of $33.83 million. Equities analysts forecast that GRAIL, Inc. will post -15.15 EPS for the current year.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.